FY26 Annual Report
Released
Released
Announcement PDF
About Cogstate
1
Cogstate Ltd Annual Report 2026
Contents
These financial statements are the
consolidated financial statements of the
Group consisting of Cogstate Limited and
its subsidiaries. A list of all subsidiaries is
included in Note 28. The financial statements
are presented in US dollars.
Cogstate Ltd (ACN 090 975 723) is a
company limited by shares, incorporated and
domiciled in Australia, and whose shares are
publicly traded on the Australian Securities
Exchange (ASX:CGS). Its registered office
is Level 32, 367 Collins Street Melbourne
Victoria 3000 Australia.
A description of the nature of the Group’s
operations and its principal activities is
included in the Directors’ Report.
We have ensured that our corporate
reporting is timely, complete and available
globally at minimum cost to the Group. All
ASX Announcements, reports, presentations
and other information are available on the
Company investor website: https://investors.
cogstate.com/.
The financial statements were authorised for
issue by the directors on 18 August 2026.
02
04
11
07
13
15
25
26
41
42
75
76
77
83
85
46
Financial Overview
Message from the Chairman and CEO
Cogstate Directors
Scalability is the Next
Strategic Frontier
Company Secretaries
Directors' Report
Auditor's Independence Declaration
Audited Remuneration Report
Financial Report
Financial Statements
Consolidated Entity Disclosure
Statement
Directors’ Declaration
Independent Auditor’s Report
Shareholder Information
Corporate Directory
Notes to the Consolidated
Financial Statements
2 Cogstate Ltd Annual Report 2026
1H26
US$
2H26
US$
FY26
US$
FY25
US$
Total Revenue 26,919,663 33,944,536 60,864,199 53,090,858
Clinical Trials Revenue 25,700,254 32,667,109 58,367,363 50,582,475
- Direct costs (excluding direct depreciation) (9,869,729) (9,477,217) (19,346,946) (16,084,199)
- SG&A costs (2,579,501) (3,103,138) (5,682,639) (3,914,477)
Clinical Trials Contribution 13,251,024 20,086,754 33,337,778 30,583,799
Contribution % 52% 61% 57% 60%
Healthcare Revenue 1,219,409 1,277,427 2,496,836 2,508,383
- Direct costs (258,559) (223,193) (481,752) (643,616)
Healthcare Contribution 960,850 1,054,234 2,015,084 1,864,767
Contribution % 79% 83% 81% 74%
Operating Expenses
Net product development & data engineering (1,397,413) (1,871,718) (3,269,131) (3,028,627)
Computer costs (1,838,271) (2,341,505) (4,179,776) (3,974,280)
Insurance (337,194) (337,865) (675,059) (735,017)
Professional fees (482,794) (643,430) (1,126,224) (1,007,727)
Marketing (81,841) (71,548) (153,389) (38,813)
Office & facilities (158,848) (200,768) (359,616) (294,791)
Travel (370,927) (347,093) (718,020) (828,260)
Other administration costs (3,016,180) (3,516,601) (6,532,781) (6,582,325)
Total Operating Expenses (7,683,468) (9,330,528) (17,013,996) (16,489,840)
EBITDA 6,528,406 11,810,460 18,338,866 15,958,726
Depreciation and amortisation (1,610,368) (1,479,992) (3,090,360) (2,946,125)
EBIT 4,918,038 10,330,468 15,248,506 13,012,601
Net interest 423,109 440,933 864,042 895,473
Net profit before tax 5,341,147 10,771,401 16,112,548 13,908,074
Net profit after tax 4,534,527 7,360,615 11,895,142 10,144,735
Financial Overview
PERFORMANCE HIGHLIGHTS
SUMMARY FINANCIAL RESULTS
REVENUE
$60.9m
(2025: $53.1m)
PROFIT BEFORE TAX
$16.1m
(2025: $13.9m)
EBITDA
$18.3m
(2025: $16.0m)
CONTRACTS SIGNED
$89.0m
(2025: $41.3m)
CONTRACTED
FUTURE REVENUE
$118.5m
(2025: $90.0m)
EBIT
$15.2m
(2025: $13.0m)
Supporting Signal Detection in
Orexin-targeted Programs
CASE STUDY
Enabling Sensitive Cognitive Endpoints in Narcolepsy Trials
CHALLENGE
A sponsor advancing an orexin-targeted
therapy for narcolepsy required cognitive
endpoints capable of detecting subtle
changes in attention and vigilance in
a small patient population. The study
design included hybrid and partially
home-based assessments, increasing
the need for sensitive, low-burden, and
repeatable measures.
COGSTATE'S ROLE
Cogstate developed and deployed
validated digital cognitive assessments,
including vigilance-based tasks designed
to measure attention and wakefulness.
These tools were selected for their
sensitivity to change, repeatability over
time, and suitability for decentralised
delivery, enabling consistent data
capture across sites and remote settings.
The assessments were integrated into
trial workflows alongside training and
monitoring protocols to ensure high
compliance and data quality.
OUTCOME
The program generated reliable cognitive
data suitable for detecting treatment-
related changes in vigilance and
attention. The use of sensitive, digitally
administered endpoints supported
confidence in trial outcomes and
contributed to progression into later-
stage development.
3
Cogstate Ltd Annual Report 2026
4 Cogstate Ltd Annual Report 2026
Dear Shareholder,
FY26 was a year of continued growth and disciplined
execution against clear strategic priorities. Building on the
foundations established in FY25, Cogstate broadened its
focus, deepened key relationships, and improved visibility
into future demand, positioning the business well for FY27
and beyond.
This resulted in record financial and commercial outcomes.
The business saw a more diversified mix of targeted
indications, increased contribution from channel and
technology partners, and continued growth in operational
scale across the clinical trials portfolio. Cogstate enters
FY27 with a strong contracted revenue base and increasing
confidence in its growth profile.
Cogstate delivered revenue of US$60.9m, up 15%, and
executed a record US$89.0m in new net sales contracts, up
116%. The Group enters FY27 with US$118.5m of contracted
future revenue, up 32% on the previous year. Of this,
$48.3 million is expected to be recognised as revenue in
FY27, up 54% from the same time last year. This provides
a strong starting position for the year ahead and reinforces
confidence in the growth outlook.
Message from the
Chairman and CEO
Pipeline Expansion Tracking to Sales Conversion
0
50
75
100
125
150
175
25
2H
FY26
1H
FY26
2H
FY25
1H
FY25
2H
FY24
1H
FY24
2H
FY23
1H
FY23
2H
FY22
1H
FY22
2H
FY21
1H
FY21
2H
FY20
1H
FY20
2H
FY19
1H
FY19
2H
FY18
1H
FY18
2H
FY17
1H
FY17
2H
FY16
1H
FY16
Number of New Opportunities
Number of
Clinical Trials
Number of New Contracts
As illustrated above Cogstate continues to see a distinct correlation between an expanded pipeline and the
successful conversion to new contracts.
5
Cogstate Ltd Annual Report 2026
Alzheimer’s Mood, Sleep & Neurological Rare Cancer, Metabolic, Other
0
20
40
60
80
100
US$ Millions
FY26
FY25
FY24
FY23
FY22
Cogstate implemented a clear capital allocation framework at the start of FY26, supporting disciplined
investment and contributing to improved financial outcomes and cash generation over the year. This was
reflected in year-on-year improvements across key metrics, with EBITDA of US$18.3m, up 15%, Net Profit before
Tax of US$16.1m, up 16%, and a cash balance of US$34.8m at year end.
The Company has declared an annual dividend of A$0.04 per share, reflecting confidence in the underlying
performance of the business and its capacity to generate sustainable returns.
Throughout the year, Cogstate demonstrated the effectiveness of its diversification strategy. Growth in sales
opportunities and new project starts was increasingly driven by awards in psychiatric and mood disorders,
rare disease, and sleep, thereby reducing reliance on Alzheimer’s disease contract awards and reinforcing the
breadth of opportunity across the Central Nervous System (CNS) landscape.
Capital Deployments Priorities and Impacts
Sales Contracts Reflecting Greater Diversification
Invest in
Growth
Return
Capital
Scale
Operations
Generate
Cash
AI-enabled products,
efficiency initiatives
EBITDA $18.3m,
strong cash balance
$12.0m buyback
since FY23 + fully
franked dividends
171 clinical trials ongoing,
up 55% year-on-year
As illustrated above, the increasing contribution of indications outside of Alzheimer's provides multiple areas for
growth as well as mitigates risk on single indication focus.
Partnerships and technology investment became
increasingly important drivers of growth and
scalability during the year, supporting a larger and
more diverse clinical trial portfolio.
As volumes increased, Cogstate continued to focus
on scaling the business. Active trials grew from 110
at 1 July 2025 to 171 at 30 June 2026. Cogstate
expects to continue to grow the number of clinical
trials that it is managing at any given time. This
underscores both the scale of the opportunity and
the importance of continued investment in systems,
workflow redesign, automation and AI-supported
delivery to maintain quality and efficiency as the
business expands, which will largely kick off this
coming year.
Throughout this year, Cogstate remained anchored
in its core differentiators: scientific credibility, global
scalability, validated digital assessments and a focus
on helping sponsors extract clearer signal from
complex clinical data to accelerate new therapies for
patients.
That combination of science, technology and
purpose continues to define Cogstate’s role in
advancing brain health research.
Cogstate also strengthened engagement with
the investor community through the launch of its
Investor Insights Series, providing shareholders and
the broader investment community with deeper
understanding of its business. This included the
Company’s inaugural Shareholder Day attended
by more than 80 investors and featuring guest
presenters from Medidata, the pharmaceutical
sector, and Cogstate’s global leadership team.
Enhancing Board leadership
It was with great pleasure that we welcomed Darryl
Inns to the Cogstate Board of Directors during the
2026 financial year. Darryl brings extensive financial,
accounting and governance experience to the
Board of Cogstate, with over 30 years experience in
executive roles at ASX listed companies where Darryl
was involved in governance, risk and compliance,
investor relations, capital markets and business
transformation. His appointment further strengthens
the Board’s financial and commercial expertise as
Cogstate continues to execute its growth strategy.
Outlook
Cogstate enters FY27 from a strong starting position,
with record contracted revenue, broader therapeutic
exposure, and growing partner-led demand.
The focus in FY27 will be on converting that
momentum into disciplined operating performance.
We are investing in the building of an operating
management platform based on workflow
orchestration, automation, and AI supported delivery
to ensure we have capability to deliver at increased
volume and differentiate from competition through a
superior customer experience.
These initiatives are intended to enhance quality,
efficiency, and resilience across a growing trial
portfolio, while providing the operating platform for
the Company’s next phase of technology-enabled
growth.
Cogstate is well positioned to build on this
momentum, with a clear strategy, a growing
opportunity set, and a measured approach to
balancing growth with delivery discipline. The
Board acknowledges the significant contribution
of management and employees in delivering these
outcomes, and thanks shareholders for their
continued support.
Martyn Myer AO Brad O’Connor
Chairman CEO & Managing Director
6 Cogstate Ltd Annual Report 2026
7
Cogstate Ltd Annual Report 2026
Scalability is the Next
Strategic Frontier
Sustainable Clinical Trials Growth
through Indication and Solution
Expansion
Cogstate is increasing the value of clinical trial
contracts through both indication and solution
expansion. Broadening into new indications
expands the addressable market, while additional
services such as central rating enhance the value
of individual trials, contributing to overall contract
value and portfolio growth.
Indication expansion
Cogstate continues to broaden its clinical trials
portfolio beyond its historical focus on Alzheimer’s
disease into psychiatric and mood disorders, sleep
disorders, and rare neurological conditions. This
indication expansion increases the size and durability
of the addressable market, reduces dependence on
any single disease area or development program,
and supports a more resilient growth profile as
different therapeutic areas move through their
respective R&D cycles.
Solution expansion
In parallel, Cogstate is expanding the range of
solutions provided within each study, evolving
from standalone digital assessments to a more
comprehensive CNS endpoint offering that includes
services such as central rating, endpoint quality
management, and data review. By deepening its
role in trial delivery, Cogstate increases the contract
value for those trials where additional services
are required, strengthens its strategic importance
to sponsors, and creates more opportunities for
recurring and follow‑on work across the life of a
clinical program.
Partnerships Extending our
Commercial Reach
Embedding Solutions with Leading Clinical
Platforms
Strategic partnerships were an increasingly
important driver of growth in FY26 with
partner‑related contracts accounting for
approximately 40% of the value of new sales
in FY26.
These relationships extend the Company’s reach
beyond its direct pharmaceutical and biotech
customers into the broader clinical trial technology
ecosystem, supporting scalable distribution, deeper
integration into sponsor workflows and stronger
validation of Cogstate’s differentiated position in
CNS endpoint innovation.
Medidata is a recent example of the success of
this approach. As one of the world’s largest clinical
trial technology platforms and part of the Dassault
Systèmes group, Medidata brings global scale,
infrastructure, and an extensive customer base,
with annual revenue of well over US$1 billion from
technology solutions supporting clinical trials.
Through the Cogstate–Medidata partnership,
validated cognitive assessments and endpoint
quality solutions are being offered at scale to
sponsors worldwide, combining Cogstate’s strength
in brain‑health measurement with Medidata’s reach
and platform capabilities.
Throughout the year, Cogstate’s focus was on
building a channel‑related pipeline, and this work
has begun to translate into meaningful revenue and a
growing number of opportunities, as our partnerships
expand across a broader range of CNS indications,
including psychiatric and mood disorders, sleep, and
rare diseases. The combined offerings streamline
commercial processes and trial operations, enhance
data quality, and broaden Cogstate’s access to
programs where central nervous system function is a
critical endpoint.
Cogstate is now collaborating with a number of
similar partners of various sizes, while a further
two potential partners have approached Cogstate,
reflecting increasing inbound interest in its
capabilities. These relationships are contributing to
an expanding channel for opportunity flow without
diluting Cogstate margins.
Together, these partnerships are becoming a
structural feature of Cogstate’s go‑to‑market
and delivery model rather than a series of
discrete initiatives. They embed Cogstate’s
science‑led endpoint solutions within widely used
technology platforms, deepen integration into
sponsor workflows and support more repeatable,
higher‑quality growth as partner‑led demand scales
over time.
8 Cogstate Ltd Annual Report 2026
Investing in Technology and AI-enabled Scale
HUMAN OVERSIGHT. SCIENTIFIC RIGOUR. OPERATIONAL SCALE.
AI-ENABLED OPERATIONS (FY27 INVESTMENT)
Clinical Trial Orchestration
A workflow automation platform
to streamline study activity
across teams, systems,
sponsors, sites, and partners.
Scaling Study Start-up
Standardised workflows and
automated task coordination to
improve speed, quality and
consistency.
Operational transparency
Shared visibility into milestones,
risks, ownership, and
dependencies supports delivery
confidence.
AI-ENABLED PRODUCTS (FY26 ACHIEVED)
AI Central Monitoring
AI-assisted review helps identify
potential administration, scoring,
and protocol-related issues,
while maintaining and scaling
clinician oversight.
AI-Powered Rater Practice
Realistic practice simulations
help raters build administration
skills through structured
feedback.
Targeted Quality Oversight
AI and analytics help focus
expert review where quality risk
is greatest.
AI IN ACTION
Scaling scientific quality through smarter products and connected
operations supporting future growth
Technology investment remained a priority in FY26
as Cogstate continued building the infrastructure
needed for its next phase of growth. During the
year, this included product enhancement through
AI Central Monitoring and AI Rater Training, both
of which are now part of the Company’s toolkit. In
parallel we continue to invest in cyber security to
enhance our posture in an ever changing threat
landscape.
The focus for the coming year will expand from
product evolution and customer experience, to
strengthening the systems, workflows and delivery
capabilities needed to support a larger and more
complex clinical trial portfolio.
As operational volumes increase, going into
FY27, Cogstate is focussing on creating a more
scalable and resilient operating model. Investment
across the year will support workflow redesign,
automation and AI-enabled initiatives intended to
improve monitoring, training, quality management,
and operational efficiency, while preserving the
scientific rigour and service quality that underpin the
Company’s reputation.
This work reflects a deliberate shift from technology
as a supporting capability to an enabler of safer
scale, with Cogstate applying AI in a practical,
purpose‑driven way to support that objective. As
the number of active trials increased materially
during FY26 and a clear pathway to further
growth emerged, management has recognised an
opportunity to use technology and AI to strengthen
workflow efficiency, enhance quality oversight and
improve the delivery experience for customers and
partners, ensuring its operating platform can support
higher volumes with continued consistency, strong
quality controls and improved leverage over time.
Taken together, these investments are designed
to support future growth, resilience, and
competitiveness. They also position Cogstate to
extend its role as a science-led CNS endpoint
innovation partner, combining validated
assessments, endpoint expertise and applied
technology to help sponsors generate clearer signal
and improve trial quality at scale.
Over time, Cogstate expects to drive operational
efficiency within cost of sales, supporting gross
margin expansion as the business scales. It will also
allow us to moderate headcount growth relative to
revenue, while ensuring our teams can keep pace
with increasing demand.
9
Cogstate Ltd Annual Report 2026
Signal and Scientific Credibility Remain
Central
Cogstate’s value is grounded in scientific rigour
and its ability to support reliable, decision-
grade outcomes in complex CNS clinical trials.
Its digital assessments are developed and
validated using rigorous psychometric and clinical
standards, underpinned by deep expertise in
neuropsychology, cognitive measurement and
CNS trial methodology across Alzheimer’s disease,
psychiatric and mood disorders, rare disease, and
sleep-related indications.
The Company’s contribution extends beyond
assessment tools. Through endpoint quality services
and standardised data review processes, Cogstate
helps reduce variability and noise, detect anomalies
and supports consistent administration across sites,
languages, and geographies, thereby improving the
reliability and integrity of trial data in areas where
measurement error can materially affect outcomes.
Cogstate also works closely with pharmaceutical
sponsors on endpoint selection, study design, and
interpretation of cognitive and functional outcomes
to help ensure measures are scientifically robust,
conclusive and aligned with regulatory expectations.
This combination of scientific rigour applied analytics
and expert oversight strengthens the interpretability
of results and gives sponsors greater confidence
in development decisions across complex CNS
programs.
Scientific credibility remains central to Cogstate’s
role in CNS drug development. Sponsors rely
on Cogstate for endpoints that are meaningful,
reproducible, and defensible under clinical
and regulatory scrutiny, supported by ongoing
investment in validation, methodological innovation,
and expert oversight.
Reducing Variability in Psychiatric
Endpoints Through Central Rating
CASE STUDY
Improving signal detection in global CNS trials
CHALLENGE
A global mood-disorder trial required
deployment of clinician-rated symptom
scales across a large, global investigator
network. The large number of sites and
variability in rater experience, combined
with compressed assessment schedules,
introduced risk of inconsistent scoring,
placebo response, and reduced ability to
detect treatment effects.
COGSTATE'S ROLE
Cogstate implemented a central rating
model, using a dedicated pool of highly
trained clinicians supported by study-
specific training, certification, and
continuous calibration. Central raters
delivered assessments via remote
telehealth-style formats, supported by
ongoing data monitoring to identify and
address variability.
This approach reduced dependence on
site-based raters and ensured consistent
application of complex psychiatric scales
across geographies.
OUTCOME
The program achieved strong
consistency in ratings and reduced
variability across sites, improving
the reliability of clinical endpoints.
This supported clearer drug-placebo
separation, more efficient execution, and
wider confidence in extending the model
across other programs.
10 Cogstate Ltd Annual Report 2026
11
Cogstate Ltd Annual Report 2026
Martyn Myer AO
BE, MESc, MSM
CHAIRMAN
Mr Myer is Chair of the Doherty
Institute at the University of
Melbourne and the board of the
Australian Chamber Orchestra.
He previously served as Deputy
Chancellor of the Council of the
University of Melbourne, President
of The Myer Foundation, one
of two principle Myer Family
philanthropic funds, President
of the Howard Florey Institute
of Experimental Physiology and
Medicine and was a director of The
Florey Institute of Neuroscience
and Mental Health, where he
participated in the transition of
the Institute’s research focus
towards diagnostic and therapeutic
neuroscience, including a focus on
degenerative brain diseases.
Committees:
Nomination Committee
Other directorships:
Current: The Doherty Institute
Council (Chair) (since January
2023), and the Australian Chamber
Orchestra (Director since 2017,
Chair since August 2023)
Previous (past 3 years):
Watertrust Australia Ltd (from 2021
to 2023)
Brad O’Connor
B Bus
MANAGING DIRECTOR AND CHIEF
EXECUTIVE OFFICER
Mr O’Connor has responsibility
for Cogstate’s overall strategic
direction and day-to-day
operations as well as development
of expansion opportunities outside
of the core clinical trials business.
Prior to taking the position of Chief
Executive Officer at Cogstate in
2005, Mr O’Connor joined Cogstate
as Chief Financial Officer and
Company Secretary in 2004. Prior
to that, Mr O’Connor held senior
positions at Spherion Group,
Australian Wine Exchange and
PricewaterhouseCoopers.
Other directorships:
Nil
Richard Mohs
PhD
INDEPENDENT NON-EXECUTIVE DIRECTOR
Dr Mohs is currently Chief
Scientific Officer for the Global
Alzheimer’s Platform (GAP)
Foundation, a non- profit devoted
to enhancing the speed and
quality of Alzheimer’s disease
research. Richard also serves as a
consultant to academic institutions,
foundations and biopharmaceutical
companies, and is a member
of the Board of Governors for
the Alzheimer’s Drug Discovery
Foundation.
Dr Mohs retired from Eli Lilly in
2015, where he held leadership
positions including Vice President
for Neuroscience Early Clinical
Development and Leader of
the Global Alzheimer’s Drug
Development Team. Before joining
Eli Lilly, Dr Mohs spent 23 years
with the Mount Sinai School of
Medicine where he was Professor
in the Department of Psychiatry
and Associate Chief of Staff for
Research at the Bronx Veterans
Affairs Medical Centre.
Committees:
Remuneration Committee,
Nomination Committee
Other directorships:
Current: Board of Governors for
the Alzheimer’s Drug Discovery
Foundation (since 2015)
Previous (past 3 years): Nil
Cogstate Directors
12 Cogstate Ltd Annual Report 2026
Ingrid Player
BEc and LLB (Hons), GAICD
INDEPENDENT NON-EXECUTIVE DIRECTOR
Ms Player brings deep healthcare
sector experience and strong
commercial expertise to the Board
of Cogstate. She has held senior
executive roles with Healthscope
Ltd, a leading private healthcare
provider in Australia, including
the former positions of Group
Executive – Legal, Governance and
Sustainability, and General Counsel
and Company Secretary from 2005
until 2019.
Ms Player also has considerable
international commercial and
regulatory experience that spans
different markets and industries,
which she gained in private legal
practice in Australia and in The
Netherlands.
Ms Player holds a Bachelor of
Economics & Bachelor of Laws
(Hons) from Monash University.
She is a graduate member of the
Australian Institute of Company
Directors.
Committees:
Audit, Risk & Compliance
Committee (Chair), Remuneration
Committee, Nomination Committee
Other directorships:
Current: Cleanaway Waste
Management Limited (since March
2021), Epworth Foundation (since
November 2021), and Integral
Diagnostics Limited (since August
2023)
Previous (past 3 years): Non-
Executive Director of HealthShare
Victoria (from 2021 to 2024)
Kim Wenn
BCompSc GAICD
INDEPENDENT NON-EXECUTIVE DIRECTOR
Ms Wenn is an experienced board
director who brings extensive
technology experience and strong
commercial expertise to the Board
of Cogstate, with over 30 years
experience in innovation roles.
Until July 2018, Kim held the role
of Chief Information Officer at
Tabcorp Holdings, an ASX50 listed
company where Kim led a team
of technology experts to drive
strategic direction through digital
transformation. Kim’s experience
includes, among other things,
business strategy, governance and
change management—with a focus
on digital disruption.
Ms Wenn holds a Bachelor of
Computer Science from Monash
University and completed an
Advanced Management Program
from Harvard University. She is a
graduate member of the Australian
Institute of Company Directors.
Committees:
Remuneration Committee
(Chair), Nomination Committee
(Chair), Audit, Risk & Compliance
Committee
Other directorships:
Current: Bupa Asia Pacific entities
(since February 2022) – Bupa
ANZ Insurance Pty Ltd, Bupa
ANZ Healthcare Holdings Pty Ltd,
Bupa HI Pty Ltd, Bupa HI Holdings
Pty Ltd and Bupa Foundation
(Australia) Limited
Previous (past 3 years): Nil
Darryl Inns
BBus, GAICD, FCPA
INDEPENDENT NON-EXECUTIVE DIRECTOR
Mr Inns brings more than 30 years’
experience in finance, accounting
and executive leadership, including
over 20 years as Chief Financial
Officer of ASX200 companies, to
the Board of Cogstate. He has held
senior executive roles with Uniti
Group Limited, M2 Group Limited,
Vocus Limited and iSelect Limited.
Mr Inns brings extensive
governance, risk and compliance
experience, with regular
engagement at Board and Audit &
Risk Committee level across highly
regulated industries, and service
as a director on subsidiary and
trustee boards. He has a strong
investor relations background,
presenting to investors and
analysts across varied market
conditions, and has led digital
transformation initiatives, including
group‑wide ERP and finance
system implementations to
improve transparency and Board
reporting.
Mr Inns holds a Bachelor of
Business (Accounting) and is a
Fellow of CPA Australia. He is
also a Graduate of the Australian
Institute of Company Directors.
Committees:
Audit, Risk & Compliance
Committee, Nomination Committee
Other directorships:
Nil
13
Cogstate Ltd Annual Report 2026
Company Secretaries
Darren Watson
BBus, CA
CHIEF FINANCIAL OFFICER AND JOINT
COMPANY SECRETARY
Darren Watson is Chief Financial
Officer for Cogstate, responsible
for the Group’s financial strategy,
driving business growth and
ensuring proper governance and
compliance. Mr. Watson leads
all aspects of finance operations
globally including corporate
accounting, financial planning
and analysis, internal audit, tax,
insurance, and procurement. Mr.
Watson is an experienced business
executive with over 20 years
working in the technology sector
across a number of international
locations.
Prior to joining Cogstate, Mr.
Watson held roles at IBM across
finance, operations and strategy
roles, most recently as Chief
Operating Officer, IBM A/NZ
Global Technology Services. His
most recent role followed stints
in Shanghai, China working in
strategy for the IBM Growth
Markets Head Office, then in
Singapore as the CFO for the IBM
GTS Asia Pacific business covering
A/NZ, ASEAN, India/South Asia,
China and South Korea.
Mr. Watson graduated from
Bendigo College of Advanced
Education with a Bachelor of
Business before joining KPMG
and completing his Chartered
Accountant qualification.
(Appointed 22 May 2026)
David Franks
BEc, CA, FFin, FGIA, JP
David is a Principal of the
Automic Group. He is a Chartered
Accountant, Fellow of the Financial
Services Institute of Australia,
Fellow of the Governance Institute
of Australia, Justice of the
Peace, Registered Tax Agent and
holds a Bachelor of Economics
(Finance and Accounting) from
Macquarie University. With over
30 years’ experience in finance,
governance and accounting, Mr
Franks has been Chief Financial
Officer, Company Secretary and/
or Director for numerous ASX
listed and unlisted public and
private companies, in a range
of industries covering energy
retailing, transport, financial
services, mineral exploration,
technology, automotive, software
development and healthcare. Mr
Franks is currently the Company
Secretary for the following ASX
Listed entities: COG Financial
Services Limited, Cogstate
Li
Share your feedback
Discover